chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain, Vaccination site rash
Clinical narrative: Extreme exhaustion and muscle aches for about a week after second shot; Extreme exhaustion and muscle aches for about a week after second shot; foggy; soreness with small rash around injection site; soreness with small rash around injection site; very low blood pressure; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 68-years-old non pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot number was not reported), via an unspecified route of administration, administered in Arm Right on 02Apr2021 14:00 (at the age of 68-year-old) as dose 2, single for covid-19 immunisation. Medical history included hypertension from an unknown date and unknown if ongoing, urticaria from an unknown date and unknown if ongoing, blood cholesterol increased from an unknown date and unknown if ongoing. Concomitant medications included atorvastatin taken for an unspecified indication, start and stop date were not reported; losartan taken for an unspecified indication, start and stop date were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Patient had no known allergies. Patient previously took BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot number was not reported), via an unspecified route of administration, administered in Arm Right on 12Mar2021 14:30 (at the age of 68-year-old) as dose 1, single for covid-19 immunisation and experienced uncontrollable shivering, 101.1 fever, severe headaches, could not stand, weak, dizzy, nausea, vomited once in bed fir 3 days. On 02Apr2021, the patient experienced extreme exhaustion and muscle aches for about a week after second shot, foggy, soreness with small rash around injection site, very low blood pressure. Felt nearly back to normal 8 days later. The patient underwent lab tests and procedures which included body temperature: 101.1 on 02Apr2021. Therapeutic measures were taken as a result of extreme exhaustion and muscle aches for about a week after second shot, foggy, soreness with small rash around injection site included Tylenol. The outcome of the events were recovered on an unspecified date in Apr2021.  No follow-up attempts are possible, information about lot/batch number cannot be obtained. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Flushing, Nasal pruritus, Paraesthesia, SARS-CoV-2 test negative, Throat tightness
Clinical narrative: flush; my lips and tongue started to tingle; my nose started to get itchy; my throat feels like it's closing; This is a spontaneous report from a contactable consumer (patient). A 52-year-old non-pregnant female patient received bnt162b2 (BNT162B2, Formulation: Solution for injection, Batch/Lot Number: ER8731), dose 2 via an unspecified route of administration, administered in Arm Left on 16Apr2021 18:15 (Age 52-year-old at the time of vaccination) as DOSE 2, SINGLE for covid-19 immunisation. Facility type vaccine included Hospital. The medical history included covid prior vaccination. The patient was tested for covid post vaccination. The patient had no known allergies. The did not have any other vaccine in four weeks. Concomitant medications taken in two weeks included levocetirizine dihydrochloride (Xyzal), MINERALS NOS, VITAMINS NOS (Centrum/ CENTRUM A TO ZINC), and naproxen sodium (Aleve) all taken for an unspecified indication, start and stop date were not reported. The historical vaccine included of BNT162B2 (Batch/Lot Number: ER8732) Dose 1 via an unspecified route of administration, administered in Arm Left on 25Mar2021 at 05:45 PM on Left arm as DOSE 1, SINGLE for covid-19 immunisation. The patient stated that, about 25-30 minutes after getting second dose, she started to get flush, her lips and tongue started to tingle on 16Apr2021 18:45. Then her nose started to get itchy, and her throat felt like it was closing on 16Apr2021 18:45. The patient was observing now, 2 hours after the vaccine. No treatment was received for the events. The patient underwent lab tests and procedures which included covid test post vaccination with a Nasal Swab. The Covid test name post vaccination was Sema4 SARS-CoV-2 Viral RNA on 17Jan2021, which was found to be Negative. The outcome of the event was reported as not recovered.  No follow up attempts are possible. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Epistaxis, Vaccination site mass
Clinical narrative: First COVID-19 vaccine: little bump on arm; First COVID-19 vaccine: nose bleed; This is a spontaneous report from a contactable consumer (patient). A 52-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for injection, Lot number: EP7534, Expiration Date: not reported) intramuscular, administered in left arm on 15Mar2021 as dose 1, single for COVID-19 immunization (at the age of 52-year-old). Medical history included ongoing sjogren's syndrome and ongoing Lupus, its been years since she was diagnosed. This condition was hereditary- her mother, grandmother and her sister had it. She did not take any medication for it , thyroid disorder, allergic to the contrast. Concomitant medication(s) included levothyroxine sodium (SYNTHROID) taken for thyroid disorder. Patient took Synthroid once a day in the morning for her thyroid, but confirmed she was taking this beyond the 2 week time period leading up to her first dose. She had been on Synthroid since she was young, a teenager. Additional Vaccines was not administered on same date of the Pfizer suspect. Patient did not receive prior vaccinations within 4 weeks and had no AEs prior vaccination. The patient experienced first covid-19 vaccine: nose bleed on 20Mar2021and first covid-19 vaccine: little bump on arm on an unspecified date. Investigation Assessment was provided. It was reported that, She just noticed when she had her first dose on 15Mar2021, the nose bleed happened within that week also. On 20Mar2021, she experienced a very bad nose bleed which she was able to get under control after 15-20 minutes. This kind of alerted her because she was not a nose bleeder. But she didn't think anything of it. She stated she left it alone and continued to not think anything of it. She never had that type of experience. She mentioned with the first dose, she didn't get a reaction on her arm. She had a little bump that went away. She felt she needed to report these nose bleeds because she took Pfizer's vaccine and was getting blood clots. The outcome of the event first covid-19 vaccine: nose bleed was unknown and first covid-19 vaccine: little bump on arm was recovered on an unspecified date.  No follow-up attempts are possible. No further information is expected.
Age: 16.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swollen lymph nodes in right armpit; This is a spontaneous report from a contactable consumer, the patient. A 16-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0162) via an unspecified route of administration in the right arm on 16Apr2021 at 14:15 (at the age of 16-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included isotretinoin (ACCUTANE); taken for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via an unspecified route of administration in the right arm on 26Mar2021 at 10:00 (at the age of 16-years-old) as a single dose for COVID-19 immunisation. On 17Apr2021 at 07:30, the patient experienced swollen lymph nodes in right armpit. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swollen lymph nodes in right armpit was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness postural, Gait inability
Clinical narrative: Dizzy any time the patient stood up or walked around; Unable to walk for a while; This is a spontaneous report from a non-contactable consumer, the patient. A 26-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 16Apr2021 at 18:15 (at the age of 26-year-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. On 17Apr2021 at 16:00, a little less than 24 hours after receiving the first dose, the patient became dizzy any time she stood up or walked around and it was nothing serious but did make the patient unable to walk for a while. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events dizzy any time the patient stood up or walked around and unable to walk for a while were resolving at the time of the report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 38.0
Sex: M
Vaccine: COVID19
Symptoms: Dysgeusia, Eating disorder, Fatigue
Clinical narrative: Food began tasting bad and continued to taste bad for 3-4 days; Impacted ability to eat; Extreme fatigue; This is a spontaneous report from a non-contactable consumer, the patient. A 38-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8737) via an unspecified route of administration in the right arm on 03Apr2021 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no known allergies to medications, food, or other products. Concomitant medications included cetirizine hydrochloride (ZYRTEC); taken for unknown indication from an unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021, approximate 48 hours after injection, the patient began to taste food bad and continued to taste bad for 3-4 days. This impacted his ability to eat. The patient also experienced extreme fatigue which started approximately 48 hours after the injection and was continuing for 5 days at the time of this report. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events food began tasting bad and continued to taste bad for 3-4 days, impacted ability to eat and extreme fatigue were recovered on an unknown date in Apr2021.  No follow-up attempts are possible. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Nausea, Pain
Clinical narrative: Headache; nausea; Body Aches; chills; Really Tired for 2 days; Injection Site hurt worse and for longer period; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 15Apr2021 at 10:00 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included thyroid (ARMOUR THYROID) and cimicifuga racemosa (BLACK COHOSH); both taken for unknown indications from unknown start dates and unknown if ongoing. The patient previously received codeine (MANUFACTURER UNKNOWN) on unknown dates for an unknown indication and experienced drug allergy. The patient also previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on an unspecified date (also reported as Mar2020) at 10:00 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Since the vaccination, the patient had not been tested for COVID-19.  On 16Apr2021, after the second vaccination, the patient experienced headache, nausea, body aches, chills, really tired for 2 days, and injection site hurt worse and for a longer period. However, the patient rated this as mild. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care visit. Therapeutic measures were not taken as a result of reported events. The clinical outcome of the event really tired was recovered on 18Apr2021 after the duration of 2 days.  The clinical outcomes of the headache, nausea, body aches, chills and injection site hurt worse were recovered on an unspecified date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Headache; nausea; Body Aches; chills; Really Tired for 2 days; Injection Site hurt worse and for longer period; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 15Apr2021 at 10:00 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included thyroid (ARMOUR THYROID) and cimicifuga racemosa (BLACK COHOSH); both taken for unknown indications from unknown start dates and unknown if ongoing. The patient previously received codeine (MANUFACTURER UNKNOWN) on unknown dates for an unknown indication and experienced drug allergy. The patient also previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on an unspecified date (also reported as Mar2020) at 10:00 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Since the vaccination, the patient had not been tested for COVID-19.  On 16Apr2021, after the second vaccination, the patient experienced headache, nausea, body aches, chills, really tired for 2 days, and injection site hurt worse and for a longer period. However, the patient rated this as mild. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care visit. Therapeutic measures were not taken as a result of reported events. The clinical outcome of the event really tired was recovered on 18Apr2021 after the duration of 2 days.  The clinical outcomes of the headache, nausea, body aches, chills and injection site hurt worse were recovered on an unspecified date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swollen lymph node under left armpit; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 16Apr2021 at 11:30 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not take any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 25Mar2021 at 09:30 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. On 18Apr2021 at 08:30, the patient experienced swollen lymph node under her left armpit. The patient was freaking out if this was a vaccine reaction or possible cancer or whatever. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event swollen lymph node under left armpit was not resolved at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Myalgia
Clinical narrative: Very tired; chills; muscle aches; This is a spontaneous report from a contactable healthcare professional, the patient. A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 16Apr2021 at 11:45 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Medical history included type 2 diabetes mellitus and COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications included metformin (MANUFACTURER UNKNOWN), simvastatin (MANUFACTURER UNKNOWN) and echinacea angustifolia, echinacea purpurea (ECHINACEA) from unknown date for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Apr2021 at 13:00, the patient experienced very tired, chills and muscle aches. Therapeutic measures were not taken as a result of the event. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events very tired, chills and muscle aches were resolved on an unknown date in Apr2021.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 31.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Decreased appetite, Fatigue, Vomiting
Clinical narrative: Chills; Vomitting; Loss of appetite; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 15Apr2021 at 17:45 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included escitalopram oxalate (LEXAPRO) for unknown indication from an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 16Apr2021 at 22:00, the patient experienced chills, vomiting, loss of appetite and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events chills, vomiting, loss of appetite and fatigue were recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site swelling, Vaccination site warmth
Clinical narrative: Large swollen red hot area at injection site; Large swollen red hot area at injection site; Large swollen red hot area at injection site; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 15Apr2021 at 10:00 (at the age of 63-year-old) as a single dose for COVID-19 immunisation. Medical history was unknown. Allergies to medications, food, or other products was unknown. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination.  Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Mar2021 at 14:45 (at the age of 63-year-old) as a single dose for COVID-19 immunisation. On 16Apr2021 at 10:00, the patient had 8cm (centimeter) and growing, large swollen red hot area at injection site. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event large swollen red hot area at injection site was not resolved at the time of the report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Oral mucosal eruption
Clinical narrative: Mouth rash, mostly under tongue some around lower molars; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EW0161) via an unspecified route of administration in the left arm on 15Apr2021 at 11:00 (at the age of 49-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medication within two weeks of vaccination. The patient had no known allergies. On 16Apr2021, the patient experienced mouth rash, mostly under tongue some around lower molars. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event mouth rash was recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Tendon pain, Vaccination site erythema, Vaccination site swelling, Vaccination site warmth
Clinical narrative: Swelling, heat, redness at site; Swelling, heat, redness at site; Swelling, heat, redness at site; left Achilles tendon pain; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 16Apr2021 at 07:00 (at the age of 52-years-old), as a single dose for COVID-19 immunisation. Medical history included allergy to shellfish and derivatives. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included melatonin (MANUFACTURER UNKNOWN), alprazolam (XANAX) and cannabis sativa (MEDICAL MARIJUANA) (as reported); all for unspecified indication from unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 26Mar2021 at 07:00 (at the age of 52-years-old), as a single dose for COVID-19 immunisation. On 16Apr2021 at 09:00, the patient experienced swelling, heat, redness at site and left achille's tendon pain. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of events. The clinical outcome of the events swelling, heat, redness at site and left achille's tendon pain was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Burning sensation, Pain, SARS-CoV-2 test
Clinical narrative: In a large area of left torso and left buttocks, a burning and stinging sensation just as if had a bad sunburn; In a large area of left torso and left buttocks, a burning and stinging sensation just as if had a bad sunburn; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ep7533) via an unspecified route of administration in the left arm on 08Apr2021 at 10:00 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have any allergies to food, medications, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not receive any concomitant medications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: en6207) via an unspecified route of administration in the left arm on 11Mar2021 at 12:00 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. On 13Apr2021, the patient experienced a burning and stinging sensation in a large area of left torso and left buttocks, just as if he had a bad sunburn but there was no visible redness or rash. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the events. On 13Apr2021, the patient underwent polymerase chain reaction (PCR) COVID test and the result was negative. The clinical outcome of the events in a large area of left torso and left buttocks, a burning and stinging sensation just as if had a bad sunburn was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoaesthesia, Paraesthesia
Clinical narrative: Numbness and tingling in left arm, hands, fingers, right arm same sensation/feelings but much less pronounced; Numbness and tingling in left arm, hands, fingers, right arm same sensation/feelings but much less pronounced; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the right arm on 12Apr2021 at 12:45 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8732), via an unspecified route of administration in the left arm on 22Mar2021 at 11:45 (at the age of 54-years-old), as a single dose for COVID-19 immunisation. On 14Apr2021, the patient experienced numbness and tingling in left arm, hands, fingers, right arm same sensation/feelings but much less pronounced. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the reported events. The clinical outcome of the events numbness and tingling in left arm, hands, fingers, right arm same sensation/feelings but much less pronounced were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Persistent right arm sore; This is a spontaneous report from a contactable physician, the patient. A non-pregnant female patient of unspecified age received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL1284) via an unspecified route of administration in the right arm on 30Dec2020 and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 01Feb2021 as a single dose for COVID-19 immunisation. Medical history included gastritis. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient did not take any concomitant medications. The patient previously took gadolinium (MANUFACTURER UNKNOWN) on an unknown date for unknown indication and experienced drug allergy. On 30Dec2020, the patient had a persistent right arm sore after the first dose and the second dose. It was three and half months after the first shot and two and half months after the second shot, and the patient still had a sore in the right arm right. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of event persistent right arm sore was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Influenza like illness
Clinical narrative: Flu like symptoms; This is a spontaneous report from a non-contactable consumer, the patient. An adult non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 10Apr2021 at 13:45 as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the right arm on 20Mar2021 at 13:45 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021, the patient experienced flu like symptoms. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the event which included treatment with Tylenol and Advil. The clinical outcome of the event flu like symptoms was resolved on an unspecified date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Cold sweat, Dysphonia, Nasal congestion, Ocular discomfort
Clinical narrative: Nasal congestion; Pressure behind eyes; Cold sweats at night; Sore throat; Hoarse voice; Loss of energy; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 15Apr2021 at 09:00 (at the age of 32-years-old), as a single dose for COVID-19 immunisation. Medical history included hypothyroidism and sulfonamide allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medication included levothyroxine (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication and unknown if ongoing. The patient previously took codeine (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced drug allergy. On 17Apr2021 at 08:00, the patient experienced nasal congestion, pressure behind eyes, cold sweats at night, sore throat, hoarse voice and loss of energy. The events did not result in doctor or other healthcare professional office/clinic visit/ emergency visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events nasal congestion, pressure behind eyes, cold sweats at night, sore throat, hoarse voice and loss of energy were resolving at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain
Clinical narrative: Nasal congestion; Pressure behind eyes; Cold sweats at night; Sore throat; Hoarse voice; Loss of energy; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 15Apr2021 at 09:00 (at the age of 32-years-old), as a single dose for COVID-19 immunisation. Medical history included hypothyroidism and sulfonamide allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medication included levothyroxine (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication and unknown if ongoing. The patient previously took codeine (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced drug allergy. On 17Apr2021 at 08:00, the patient experienced nasal congestion, pressure behind eyes, cold sweats at night, sore throat, hoarse voice and loss of energy. The events did not result in doctor or other healthcare professional office/clinic visit/ emergency visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events nasal congestion, pressure behind eyes, cold sweats at night, sore throat, hoarse voice and loss of energy were resolving at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Vertigo
Clinical narrative: I had vertigo approx. 60 hours after vaccine. It lasted until around 3:00 pm the same day.; This is a spontaneous report from a contactable consumer, the patient. A 75-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Apr2021 at 11:45 (at the age of 75-year-old) as a single dose for COVID-19 immunisation. Medical history included coronary heart disease, kidney disorder (stage 3) and type II diabetes mellitus. Concomitant medications included metformin (MANUFACTURER UNKNOWN), metoprolol (MANUFACTURER UNKNOWN), losartan (MANUFACTURER UNKNOWN) and ezetimibe (ZETIA), all for unknown indication from an unknown date and unknown if ongoing. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 16Apr2021 at 06:00, approx. 60 hours after vaccine the patient experienced vertigo. It lasted until around 15:00 the same day. The patient was not sure if this was a result of the vaccine. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event vertigo was recovered on 16Apr2021 at 15:00.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Pain in extremity
Clinical narrative: Sore arm; Chills; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: W0162) via an unspecified route of administration in the left arm on 17Apr2021 at 15:00 (at the age of 36-years-old), as a single dose for COVID-19 immunisation. Medical history included allergy to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included clindamycin (MANUFACTURER UNKNOWN) for unspecified indications from unknown dates and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient previously took sulfur (MANUFACTURER UNKNOWN) for unspecified indications from unknown date and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 26Mar2021 at 15:30 (at the age of 36-years-old), as a single dose for COVID-19 immunisation. On 17Apr2021 at 16:30, the patient experienced sore arm, chills, fatigue. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events sore arm, chills, fatigue was recovered on an unknown date in Apr2021.  No follow-up attempts are possible. No further information is expected
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Dizziness, Headache
Clinical narrative: Weird stabbing pain in my lower left abdomen. The pain pulsates randomly and goes away within seconds of its start.; Continually having dizziness and headaches.; Continually having dizziness and headaches.; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 24Mar2021 at 10:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included anxiety, obesity, depression and COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient received other medicines (unspecified) within two weeks prior to the COVID-19 vaccine. The patient previously took codeine (MANUFACTURER UNKNOWN) for unknown indication on an unknown date and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Mar2021 at 04:00, the patient experienced weird stabbing pain in lower left abdomen. The pain pulsated randomly and goes away within seconds of its start. The patient continually had dizziness and headaches. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events weird stabbing pain in lower left abdomen, pain pulsates randomly and goes away within seconds of its start, dizziness and headaches were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Confusional state, Muscle spasms, Muscular weakness, Nausea
Clinical narrative: weakness; nausea; vomiting; confusion; persistent muscle weakness; movement pain all over; pain all over including injection site; Muscle cramps; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 08Apr2021 at 19:45 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. Medical history included post-traumatic stress disorder (Ptsd), depression, sleep apnea, asthma, migraine and carpal tunnel syndrome. The patient was allergic to wasps, yellow jackets and white-faced hornets. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other medications (unspecified) within two weeks prior to vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 at 20:45, the patient experienced weakness, nausea, vomiting, confusion, persistent muscle weakness, movement pain all over including injection site and muscle cramps. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of events. On an unknown date, the patient underwent nasal swab test and the result was negative. Since the vaccination, the patient had been tested for COVID-19.The clinical outcome for the events weakness, nausea, vomiting, confusion, muscle weakness, pain upon movement including injection site and muscle cramps were not recovered.   No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, SARS-CoV-2 test, Vaccination site pain, Vomiting
Clinical narrative: weakness; nausea; vomiting; confusion; persistent muscle weakness; movement pain all over; pain all over including injection site; Muscle cramps; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 08Apr2021 at 19:45 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. Medical history included post-traumatic stress disorder (Ptsd), depression, sleep apnea, asthma, migraine and carpal tunnel syndrome. The patient was allergic to wasps, yellow jackets and white-faced hornets. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other medications (unspecified) within two weeks prior to vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 at 20:45, the patient experienced weakness, nausea, vomiting, confusion, persistent muscle weakness, movement pain all over including injection site and muscle cramps. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of events. On an unknown date, the patient underwent nasal swab test and the result was negative. Since the vaccination, the patient had been tested for COVID-19.The clinical outcome for the events weakness, nausea, vomiting, confusion, muscle weakness, pain upon movement including injection site and muscle cramps were not recovered.   No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Dizziness, Feeling abnormal, Headache, Lethargy
Clinical narrative: Mild wooziness the night of the 2nd vaccine; Headache and lethargy the next day or two; Headache and lethargy the next day or two; Just felt a bit strange; Lower energy than usual for a few days; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER 8727) via an unspecified route of administration in the left arm on 12Apr2021 at 15:00 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. The patient had no other medical history. The patient had no known allergies to medications, food, or other products. Concomitant medication received within two weeks of vaccination was not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER 8727) via an unspecified route of administration in the left arm on 22Mar2021 at 14:30 (at the age of 59-years-old) as a single dose for COVID-19 immunisation and experienced no reaction whatsoever to first dose. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced mild wooziness on 12Apr2021 at 18:00, the night of the second vaccine. Headache and lethargy the next day or two on an unknown date in Apr2021. Aspirin helped the headache. The patient just felt a bit strange on an unknown date in Apr2021. Lower energy than usual for a few days from an unknown date in Apr2021. Therapeutic measures were taken as a result of headache and included treatment with Aspirin. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events mild wooziness the night of the second vaccine; headache and lethargy the next day or two; just felt a bit strange; lower energy than usual for a few days was resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.